Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B.

Hepatology. 2010 Sep;52(3):886-93. doi: 10.1002/hep.23785.

PMID:
20683932
2.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group.

N Engl J Med. 2006 Mar 9;354(10):1011-20. Erratum in: N Engl J Med. 2006 Apr 27;354(17):1863.

3.

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group.

N Engl J Med. 2006 Mar 9;354(10):1001-10.

4.

Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.

Wu IC, Lai CL, Han SH, Han KH, Gordon SC, Chao YC, Tan CK, Sievert W, Tanwandee T, Xu D, Neo BL, Chang TT.

Hepatology. 2010 Apr;51(4):1185-9. doi: 10.1002/hep.23424.

PMID:
20044806
5.

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection.

Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T, Omata M.

J Hepatol. 2010 Jun;52(6):791-9. doi: 10.1016/j.jhep.2009.12.036. Epub 2010 Mar 24.

PMID:
20409606
6.

Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis.

Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, Jiao J, Wang JB.

World J Gastroenterol. 2015 Jul 7;21(25):7869-76. doi: 10.3748/wjg.v21.i25.7869.

7.

Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?

Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H.

J Gastroenterol Hepatol. 2009 Mar;24(3):429-35. doi: 10.1111/j.1440-1746.2008.05760.x. Epub 2009 Feb 15.

PMID:
19226381
8.

Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.

Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R.

Am J Gastroenterol. 2008 Nov;103(11):2776-83. doi: 10.1111/j.1572-0241.2008.02086.x. Epub 2008 Aug 21. Erratum in: Am J Gastroenterol. 2009 Feb;104(2):540.

PMID:
18721244
9.

Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.

Buti M, Morillas RM, Prieto M, Diago M, Pérez J, Solà R, Bonet L, Palau A, Testillano M, García-Samaniego J, Rodríguez M; ORIENTE Study Group.

Eur J Gastroenterol Hepatol. 2012 May;24(5):535-42. doi: 10.1097/MEG.0b013e3283511287. Erratum in: Eur J Gastroenterol Hepatol. 2012 Aug;24(8):999.

PMID:
22382708
10.

Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.

Xu B, Lin L, Xu G, Zhuang Y, Guo Q, Liu Y, Wang H, Zhou X, Wu S, Bao S, Cai W, Xie Q.

J Gastroenterol Hepatol. 2015 Feb;30(2):372-8. doi: 10.1111/jgh.12718.

PMID:
25167956
11.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Hepatol. 2012 Sep;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037. Epub 2012 May 30.

PMID:
22659518
12.

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.

van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group.

Liver Int. 2006 May;26(4):399-405.

PMID:
16629642
13.

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.

Gastroenterology. 2007 Nov;133(5):1437-44. Epub 2007 Aug 14.

PMID:
17983800
14.

Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.

Güzelbulut F, Ovünç AO, Oetinkaya ZA, Senates E, Gökden Y, Saltürk AG, Sezikli M, Ozkara S, Cetinkaya F.

Hepatogastroenterology. 2012 Mar-Apr;59(114):477-80. doi: 10.5754/hge11426.

PMID:
21940383
15.

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.

Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group.

Hepatology. 2008 Jul;48(1):99-108. doi: 10.1002/hep.22323.

PMID:
18537189
16.

Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients.

Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, Chen CW.

J Viral Hepat. 2010 Mar;17 Suppl 1:51-8.

PMID:
20586934
17.

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.

J Viral Hepat. 2010 Jan;17(1):16-22. doi: 10.1111/j.1365-2893.2009.01146.x. Epub 2009 Jul 19.

PMID:
19622117
18.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
19.

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U.

Hepatology. 2010 Feb;51(2):422-30. doi: 10.1002/hep.23327.

PMID:
20049753
20.

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.

Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV.

Adv Ther. 2015 Aug;32(8):727-41. doi: 10.1007/s12325-015-0232-2. Epub 2015 Sep 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk